LMC | Manna Research will be at the 2017 Global Sites Solutions Summit in Boca Raton, FL

LMC | Manna Research will be at the 2017 Global Sites Solutions Summit in Boca Raton, FL

Representatives of LMC|Manna Research will be at the 2017 Global Sites Solutions Summit in Boca Raton, Florida (October 6th to 8th)   Conference Attendees: Karri Venn, President, Research & Nazneen Qureshi, Manager, Patient Engagement   Please contact Ms. Venn using the information listed below to schedule a meeting during her time at the 2017 Global Site Solutions Summit in Florida and come cheer on Ms. Qureshi as she presents on behalf of LMC|Manna as one of the top 3 finalists for the Site Patient Recruitment Innovation Award (SPRIA).http://sitesolutionssummit.com/site-patient-recruitment-innovation-award/   Karri Venn Incoming Calls: 647-274-4133 Text Messaging: 815-919-6396 (while in USA) karri.venn@LMC.ca We would love to set up a meeting with you to discuss our growth and new potential therapeutic capabilities at LMC|Manna Research while in Florida. Let us know when this will work for...
LMC | Manna Research will be at the 8th Annual SCOPE Summit in Miami, FL

LMC | Manna Research will be at the 8th Annual SCOPE Summit in Miami, FL

LMC | Manna Research’s Karri Venn (President, Research), will be at the 8th Annual SCOPE Summit in Miami, FL from January 24th-26th 2017. If you are interested to connect while we are in Miami, please use the information listed below to schedule a meeting: Karri Venn Incoming Calls: 647-274-4133 Text Messaging (at the conference): 815-919-6396 karri.venn@LMC.ca Looking forward to connect in Miami! #SCOPE2017...
GSK Shingles Vaccine Remains Effective After Four Years: Study

GSK Shingles Vaccine Remains Effective After Four Years: Study

GlaxoSmithKline’s experimental vaccine to prevent the intensely painful condition known as shingles remained 90 percent effective in people over age 70 even four years after receiving the injection, according to data published on Wednesday. In clinical trials, GSK’s Shingrix has shown greater protection for older recipients than what has been demonstrated by Merck & Co’s rival Zostavax vaccine. The drug is one of GSK’s biggest new product hopes. It plans to file for U.S., European and Japanese approval this year, and the vaccine could reach the market in 2017. The latest four-year data on Shingrix, which appears in the New England Journal of Medicine, shows it may also provide an additional significant advantage by maintaining its effectiveness over time. The risk of shingles, which is caused by reactivation of the chicken pox virus, increases with age. There are about 1 million cases of shingles in the United States each year, according to the Centers for Disease Control and Prevention. To read more from this article, please click...
Herpes Zoster Subunit Vaccine Shows Great Efficacy in Adults 70 and Older

Herpes Zoster Subunit Vaccine Shows Great Efficacy in Adults 70 and Older

Great news in the world of vaccines! In the ZOE-70 Study, the herpes zoster subunit vaccine (HZ/su) was showed to decrease the risk of herpes zoster by 89.8% in adults 70 years of age and older. Herpes zoster, or shingles, results from the reactivation of latent varicella–zoster virus (VZV) and is recognized as a painful rash on the skin (postherpetic neuralgia). It also affects nerve fibers , causing burning pain that lasts long after the rash and blisters of shingles disappear. See the video below to learn more about this study and some of the exciting results! To read more about this trial click here...

Profil Institute and LMC Diabetes Launch Strategic Partnership to Conduct Cross-Border Multi-Site Trials in Diabetes and Metabolism

Collaboration Brings Together Leading U.S. Metabolism-Focused CRO and Largest Canadian Diabetes Site Network SAN DIEGO AND TORONTO, June 10, 2016 /PRNewswire/ –  Profil Institute for Clinical Research, a science-driven clinical research organization (CRO) focused exclusively on metabolic diseases, and LMC Diabetes & Endocrinology, North America’s largest network of investigator sites for diabetes clinical research, announced today a strategic alliance focused on the conduct of cross-border, multi-site clinical research of investigational drugs and devices for diabetes and related metabolic disorders. Under the terms of the agreement, Profil Institute will expand its investigator network to include LMC’s 13 metabolism-focused clinical research sites in Canada. Profil Institute will also provide clinical development planning as well as oversight of regulatory submissions to the U.S. FDA and Health Canada. Profil Institute is the only full scope CRO in the U.S. that is exclusively focused on metabolic diseases.  The company’s experience encompasses every clinically relevant drug class in diabetes, including early phase studies for many of the diabetes medications and devices on the market today. Headquartered in San Diego, Profil Institute operates a dedicated clinical research facility that has completed over 240 phase I-IIa studies, as well as a network of more than 50 partnering sites for multi-center trials, which will now be expanded to include LMC’s 13 metabolism-focused sites in Canada. LMC is the largest private diabetes clinical research network in North America. The company has conducted over 600 clinical trials across its 13 centers in Canada.  LMC sites adhere to 21 C.F.R. (Parts 50, 56), 45 C.F.R. (Part 46) and GCP standards to ensure clinical data is accepted by international regulatory agencies, including...